Supriya Lifescience Ltd approves Q2 FY27 results with ₹206.3 crore revenue and appoints Mangesh Vaze as COO
- Revenue rose 8.7% sequentially and 3.2% year on year; calculated EBITDA operating margin was 23.1%.
- Net profit was ₹29.3 crore, up 21.7% sequentially and down 42.0% year on year.
- Vaze’s appointment as Chief Operating Officer and Senior Management Personnel is effective 6 November 2026.
- No exceptional items were reported; the limited review noted no material misstatement.
